ImmunityBio commences CD19 t-haNK cell therapy trial for NHL
The trial is the first of its kind in South Africa to explore cellular-targeted NK cell therapy.
Clinical Trials
OKYO Pharma doses first subject in OK-101 Phase II trial for NCP
Calluna completes CAL101 Phase I clinical study for fibrotic conditions
Repare Therapeutics’ individualised anaemia management trial shows promise
Genelux doses first subject in Phase II trial of NSCLC treatment
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint
Otsuka’s sibeprenlimab shows promise in Phase III IgA nephropathy trial
Galderma reports data from Phase III trial of anti-ageing product RelabotulinumtoxinA
